Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Ts172

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07231029Phase 1RecruitingPrimary

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

NCT05624944Phase 1CompletedPrimary

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

Showing all 2 trials

Research Network

Common Treatments

  • Ts1721
  • Ts142 5 Mg1

Active Sponsors

  • Taisho Pharmaceutical Co., Ltd.2

Top Investigators

Activity Timeline